Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 3B, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Evaluate the Efficacy and Safety of Apremilast (CC-10004) Monotherapy in Subjects With Active Psoriatic Arthritis

Next Previous
X
Search
Trial Profile

A Phase 3B, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Evaluate the Efficacy and Safety of Apremilast (CC-10004) Monotherapy in Subjects With Active Psoriatic Arthritis

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 03 Jan 2024

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Apremilast (Primary)
  • Indications Psoriatic arthritis
  • Focus Registrational; Therapeutic Use
  • Acronyms ACTIVE
  • Sponsors Amgen; Celgene Corporation

    • Most Recent Events

    • 15 Nov 2023 Results assessing the effects of apremilast on cardiometabolic parameters over 52 weeks in patients with active psoriatic arthritis from 5 studies PALACE 1-4 and ACTIVE, presented at the ACR Convergence 2023.
    • 03 Jun 2023 Results of pooled analysis (n=781 from studies PALACE 1 to 4 and ACTIVE) assessing the effects of APR on cardiometabolic parameters over 52 weeks in patients with active psoriatic arthritis presented at the 24th Annual Congress of the European League Against Rheumatism
    • 30 May 2023 Results presented in an Amgen Media Release.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top